Source comparison
CJC-1295 Dosing Protocols: Age-Specific Comparison
30–45 years 1500–2000 mcg 2–3× weekly 250–350 Retest at 12 weeks Higher dose tolerated due to preserved insulin sensitivity and faster hepatic IGF-1 synthesis 45–60 years 1200–1500 mcg 2× weekly 220–280 Retest at 10 weeks Moderate dose reduction reflects decli
This comparison does not assign a generated winner or score.
- 30–45 years
- 1500–2000 mcg
- 2–3× weekly
- 250–350
- Retest at 12 weeks
- Higher dose tolerated due to preserved insulin sensitivity and faster hepatic IGF-1 synthesis
- 45–60 years
- 1200–1500 mcg
- 2× weekly
- 220–280
- Retest at 10 weeks
- Moderate dose reduction reflects declining GH receptor density and increased metabolic caution
- 60+ years
- 1000–1200 mcg
- 180–250
- Retest at 8 weeks
- Conservative dosing prevents glucose dysregulation; slower titration accommodates age-related insulin resistance
- 60+ with baseline IGF-1 <80 ng/mL
- 200–260
- Retest at 6 weeks
- Severe deficiency requires higher starting dose but closer monitoring for adverse metabolic effects
- 60+ with HbA1c >5.7%
- 600–800 mcg
- 160–200
- Pre-diabetic patients require lowest effective dose; pair with carbohydrate restriction and fasting protocol
- 60+ with thyroid dysfunction
- 800–1000 mcg
- 170–220
- Retest at 8 weeks plus thyroid panel
- Subclinical hypothyroidism blunts GH response; optimise thyroid function before escalating CJC-1295 dose